Undetectable circulating tumor DNA confirms the inability of pseudomyxoma peritonei to systemic dissemination.

Autor: Villarejo Campos P; IIS-FJD. UAM. Fundación Instituto de Investigación Sanitaria Fundación Jiménez Diaz, Madrid, Spain., Vázquez-Borrego MC; GE09 Research in Peritoneal and Retroperitoneal Oncological Surgery, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain; Department of Biochemistry and Molecular Biology, University of Córdoba, Spain., Martínez-Quintanilla J; Translational Program, Stem Cells and Cancer Laboratory, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Cabot D; Translational Program, Stem Cells and Cancer Laboratory, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Romero-Ruíz A; GE09 Research in Peritoneal and Retroperitoneal Oncological Surgery, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain; Department of Biochemistry and Molecular Biology, University of Córdoba, Spain., Granados-Rodríguez M; GE09 Research in Peritoneal and Retroperitoneal Oncological Surgery, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain; Department of Biochemistry and Molecular Biology, University of Córdoba, Spain., Bura FI; GE09 Research in Peritoneal and Retroperitoneal Oncological Surgery, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain; Department of Biochemistry and Molecular Biology, University of Córdoba, Spain., García-Arranz M; IIS-FJD. UAM. Fundación Instituto de Investigación Sanitaria Fundación Jiménez Diaz, Madrid, Spain., García-Olmo D; IIS-FJD. UAM. Fundación Instituto de Investigación Sanitaria Fundación Jiménez Diaz, Madrid, Spain. Electronic address: damian.garcia@uam.es., Arjona-Sánchez A; GE09 Research in Peritoneal and Retroperitoneal Oncological Surgery, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain; Unit of Surgical Oncology, Department of Surgery, Reina Sofia University Hospital, Cordoba, Spain. Electronic address: alvaroarjona@hotmail.com.
Jazyk: angličtina
Zdroj: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology [Eur J Surg Oncol] 2024 Jul; Vol. 50 (7), pp. 108395. Date of Electronic Publication: 2024 May 09.
DOI: 10.1016/j.ejso.2024.108395
Abstrakt: The study of circulating tumor DNA (ctDNA) plays a pivotal role in advancing precision oncology, providing valuable information for individualized patient care and contributing to the ongoing effort to improve cancer diagnosis, treatment, and management. However, its applicability in pseudomyxoma peritonei (PMP) remains unexplored. In this multicenter retrospective study involving 21 PMP patients, we investigated ctDNA presence in peripheral blood using three distinct methodologies. Despite mucinous tumor tissues exhibiting KRAS and GNAS mutations, ctDNA for these mutations was undetectable in blood samples. In this pilot study, circulating tumor DNA was not detected in blood when the tumor harbored mutations of known significance. In the future, a study with a larger sample size is needed to confirm these findings and to determine whether ctDNA could identify patients at risk for early recurrence and/or systemic metastases.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(© 2024 Elsevier Ltd, BASO ∼ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.)
Databáze: MEDLINE
Externí odkaz: